Adriano Lazzarin

Q: What Schools Are Affiliated With Adriano Lazzarin

Adriano Lazzarin is affiliated with the following schools: University of Lausanne, University of Milan, University of Parma, Vita-Salute San Raffaele University, University of Brescia, University of Padua, University of Geneva, University of Bologna

Adriano Lazzarin's AcademicInfluence.com Rankings

Adriano Lazzarin

Computer Science

#5882

World Rank

#6206

Historical Rank

Machine Learning

#1728

World Rank

#1751

Historical Rank

Artificial Intelligence

#1971

World Rank

#2005

Historical Rank

Database

#3005

World Rank

#3133

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Adriano Lazzarin's Degrees

PhD Computer Science University of Padua
Masters Computer Engineering University of Milan
Bachelors Computer Engineering University of Milan

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Adriano Lazzarin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Adriano Lazzarin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. (2004) (1068)
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. (2003) (652)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (2009) (615)
Raltegravir with optimized background therapy for resistant HIV-1 infection. (2008) (570)
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial (2007) (560)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. (2008) (544)
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials (2007) (470)
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. (2010) (405)
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial (2011) (398)
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. (2008) (353)
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years (2007) (336)
A controlled trial of zidovudine in primary human immunodeficiency virus infection. (1995) (324)
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system (1993) (306)
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. (1997) (303)
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study (2014) (286)
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. (2001) (284)
The Efficiency of Male‐to Female and Female‐to‐Male Sexual Transmission of the Human Immunodeficiency Virus: A Study of 730 Stable Couples (1994) (280)
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study (2012) (273)
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures (2005) (271)
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. (2000) (267)
Elevated cerebrospinal fluid levels of monocyte chemotactic protein‐1 correlate with HIV‐1 encephalitis and local viral replication (1998) (262)
Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV (2004) (258)
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study (2007) (255)
Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. (1997) (240)
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses (2010) (230)
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy (2020) (221)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (2019) (221)
Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients (1996) (216)
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures (2006) (216)
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. (2010) (200)
Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. (1998) (200)
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors (2020) (194)
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials (2009) (193)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial (2017) (192)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial (2007) (188)
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. (2015) (185)
Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. (2001) (179)
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. (2002) (174)
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. (2011) (170)
Elevated alpha–tumor necrosis factor levels in spinal fluid from HIV‐1–infected patients with central nervous system involvement (1991) (169)
TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV‐infected patients (1994) (165)
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) (2006) (164)
A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. (1991) (160)
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. (2007) (158)
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials (2005) (156)
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. (2000) (153)
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. (1999) (151)
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. (2002) (150)
Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. (1994) (147)
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. (2005) (145)
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials (2013) (142)
Antigen-driven C–C Chemokine-mediated HIV-1 Suppression by CD4+ T Cells from Exposed Uninfected Individuals Expressing the Wild-type CCR-5 Allele (1997) (138)
Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. (2011) (137)
Coronaviridae and SARS-associated Coronavirus Strain HSR1 (2004) (134)
Gender Differences in Antiretroviral Drug–Related Adipose Tissue Alterations: Women Are at Higher Risk Than Men and Develop Particular Lipodystrophy Patterns (2003) (134)
CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro1 (2000) (131)
Real-Time PCR Assay for Clinical Management of Human Immunodeficiency Virus-Infected Patients with Visceral Leishmaniasis (2003) (128)
Cerebrospinal fluid HIV‐1 RNA levels: correlation with HIV encephalitis (1998) (128)
Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. (1992) (126)
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. (2013) (125)
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. (1985) (120)
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. (2004) (118)
Man-to-Woman Sexual Transmission of the Human Immunodeficiency Virus: Risk Factors Related to Sexual Behavior, Man’s Infectiousness, and Woman’s Susceptibility (1991) (118)
Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. (1996) (117)
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. (2002) (116)
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study (2013) (115)
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing (2014) (112)
HLA-ASSOCIATED SUSCEPTIBILITY TO ACQUIRED IMMUNODEFICIENCY SYNDROME IN ITALIAN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION (1986) (110)
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. (2011) (110)
Virological rebound after suppression on highly active antiretroviral therapy (2003) (108)
Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. (1988) (107)
Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. (2000) (106)
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. (2011) (105)
Mother-to-Child Transmission of Hepatitis C Virus Detected by Nested Polymerase Chain Reaction (1992) (104)
Focal lymphocytic myocarditis in acquired immunodeficiency syndrome (AIDS): a correlative morphologic and clinical study in 26 consecutive fatal cases. (1988) (103)
Rapid Diagnosis of Mycobacterial Infections and Quantitation of Mycobacterium tuberculosis Load by Two Real-Time Calibrated PCR Assays (2003) (102)
Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection Effect of parenteral treatment with SAMe (1995) (101)
Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. (1986) (99)
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. (2000) (99)
TRIZAL study: switching from successful HAART to TrizivirTM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results (2003) (92)
Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. (1999) (91)
Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment (2004) (90)
Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. (2006) (89)
Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART (2010) (89)
Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. The Northern Italian Seronegative Drug Addicts (NISDA) Study. (1992) (88)
Divergent regulation of HIV‐1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP‐1α, and MCP‐3, and enhancement by MCP‐1 (2000) (87)
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. (2006) (87)
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. (2014) (87)
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients (2001) (86)
Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks (2005) (85)
Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. (2000) (84)
The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: Study of 43 cases with review of the literature (2011) (83)
Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy (2012) (82)
AIDS, zinc deficiency, and thymic hormone failure. (1988) (81)
Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. (2003) (79)
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine (1994) (78)
Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection? (1997) (78)
Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Italian Study Group on HIV Heterosexual Transmission. (1991) (78)
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies (2009) (77)
Replication of hepatitis C virus in B lymphocytes (CD19+) (1999) (77)
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. (2003) (76)
Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy (2000) (76)
Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. (1985) (74)
Survival of Zidovudine-Treated Patients With AIDS Compared With That of Contemporary Untreated Patients (1992) (74)
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. (2005) (73)
Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. (2000) (72)
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations (2004) (72)
CCR2 Polymorphism and HIV Disease (1998) (70)
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. (2011) (70)
Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. (1995) (68)
Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. (2006) (68)
Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study (2010) (67)
Osteoprotegerin and bone turnover markers in heavily pretreated HIV‐infected patients (2005) (66)
Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis (2003) (66)
AIDS‐defining diseases in 250 HIV‐infected patients; a comparative study of clinical and autopsy diagnoses (1992) (65)
Plasma levels of soluble CD30, tumour necrosis factor (TNF)‐&agr; and TNF receptors during primary HIV‐1 infection: correlation with HIV‐1 RNA and the clinical outcome (1996) (63)
Changes in use of antiretroviral therapy in regions of Europe over time (1998) (63)
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. (2010) (63)
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study (2001) (63)
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis (2008) (62)
Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features (2009) (61)
Herpes simplex virus infections of the central nervous system in human immunodeficiency virus-infected patients: clinical management by polymerase chain reaction assay of cerebrospinal fluid. (1998) (60)
JC polyomavirus mutants escape antibody-mediated neutralization (2015) (60)
Polymerase chain reaction for Toxoplasma gondii DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions (1994) (60)
Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. (1999) (59)
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. (2017) (59)
Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. (2000) (59)
The natural history of HIV infection in intravenous drug users: risk of disease progression in a cohort of seroconverters. (1989) (59)
Expression of CD4 on human peripheral blood neutrophils. (2003) (58)
Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users (1995) (58)
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls (2020) (57)
The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy (2011) (57)
Early diagnosis of HIV infection in infants. (1989) (56)
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. (2010) (55)
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. (2007) (55)
Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study (2008) (55)
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. (2009) (54)
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. (2010) (54)
Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials (2004) (54)
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism (2010) (53)
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience (2010) (53)
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS. (2002) (53)
Hyperbilirubinemia during Atazanavir Treatment in 2,404 Patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts (2009) (52)
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients (1996) (52)
Epidemiology of cryptosporidiosis among European AIDS patients. (1996) (51)
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. (2000) (51)
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. (2007) (51)
Access denied? The status of co-receptor inhibition to counter HIV entry (2007) (51)
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO (2014) (51)
Selected Pool of Peptides from ESAT-6 and CFP-10 Proteins for Detection of Mycobacterium tuberculosis Infection (2004) (50)
The preventive phase I trial with the HIV-1 Tat-based vaccine. (2009) (50)
CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. (2004) (49)
Central Nervous (2010) (49)
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score (2007) (49)
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts. (1988) (48)
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial (2005) (48)
Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. (1993) (48)
Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. (2006) (48)
Infection of circulating CD34+ cells by HHV-8 in patients with Kaposi's sarcoma. (1999) (48)
Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. (2005) (47)
Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV‐infected patients (1997) (47)
Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial (2011) (46)
IgM, IgG and IgA rheumatoid factors and circulating immune complexes in patients with AIDS and AIDS-related complex with serological abnormalities. (1987) (46)
Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals (2003) (46)
Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. (2016) (45)
Use of polymerase chain reaction assays of aqueous humor in the differential diagnosis of retinitis in patients infected with human immunodeficiency virus. (1997) (45)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study (2008) (45)
The therapeutic phase I trial of the recombinant native HIV-1 Tat protein (2008) (45)
Mother-to-child transmission of hepatitis C virus detected by nested polymerase chain reaction. (1992) (45)
Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood Mononuclear Cells and in the U937 Cell Line (1998) (45)
Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease. (1998) (44)
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen (2010) (44)
Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV Infection (2000) (44)
The urokinase receptor is overexpressed in the AIDs dementia complex and other neurological manifestations (2004) (44)
In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high‐risk HIV‐negative intravenous drug users (1995) (43)
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial (2015) (43)
Enfuvirtide: the first HIV fusion inhibitor (2005) (43)
Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells (2007) (43)
Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. (2000) (43)
Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. (1996) (42)
Incidence and prevalence trends of HIV infection in intravenous drug users attending treatment centers in Milan and northern Italy, 1986-1990. (1992) (42)
Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy. (2001) (42)
Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. (2003) (42)
Positive modification of injecting behavior among intravenous heroin users from Milan and northern Italy 1987-1989. NISDA Study. (1991) (42)
Liver Fibrosis in HIV-Positive Patients With Hepatitis C Virus: Role of Persistently Normal Alanine Aminotransferase Levels (2006) (42)
Role of brain biopsy in the management of focal brain lesions in HIV-infected patients (2000) (42)
Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. (2001) (42)
Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid. (1995) (42)
Etravirine for the treatment of HIV infection (2008) (41)
Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma (2011) (41)
Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. (2009) (41)
Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK (2012) (40)
Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. (2005) (40)
Antiretroviral Treatment Strategies and Immune Reconstitution in Treatment-naive HIV-Infected Patients with Advanced Disease (2007) (40)
Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy (2008) (39)
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. (2000) (39)
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count (2000) (39)
Risk factors for woman-to-man sexual transmission of the human immunodeficiency virus. Italian Study Group on HIV Heterosexual Transmission. (1994) (39)
Kaposi's sarcoma and AIDS: frequency of gastrointestinal involvement and its effect on survival. A prospective study in a heterogeneous population. (1991) (39)
Monocyte-derived macrophage function in HIV-infected subjects: in vitro modulation by rIFN-gamma and rGM-CSF. (1992) (38)
Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. (1996) (38)
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. (1997) (38)
Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/Δccr5) genotype is neither essential nor sufficient for protection against disease progression (1997) (38)
The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development. (2005) (37)
A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers (2017) (37)
Fc Receptors Expression and Function in Mononuclear Phagocytes from AIDS Patients: Modulation by IFN‐Gamma (1994) (37)
Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. (2000) (37)
HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. (1996) (37)
Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression. (2007) (37)
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study (2014) (36)
Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinaemia and hepatitis C virus (HCV) infection. (1997) (36)
Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. (1995) (36)
An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe (2010) (36)
HIV-related severe thrombocytopenia in intravenous drug users: prevalence, response to therapy in a medium-term follow-up, and pathogenetic evaluation. (1990) (36)
Induction of Murine Mucosal CCR5-Reactive Antibodies as an Anti-Human Immunodeficiency Virus Strategy (2005) (36)
Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51) (2008) (36)
Discrete regions of HIV‐1 gp41 defined by syncytia‐inhibiting affinity‐purified human antibodies (1993) (35)
Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy (1999) (35)
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. (2016) (34)
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings (2014) (34)
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. (2012) (34)
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine (2001) (34)
Transplacental transmission of HTLV-III virus. (1986) (34)
Detection of Rifampin Resistance in Mycobacterium tuberculosis by Double Gradient-Denaturing Gradient Gel Electrophoresis (1999) (34)
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (2020) (34)
Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease (2004) (34)
[The inflammatory process]. (1990) (34)
Hodgkin disease and infection with the human immunodeficiency virus (HIV) in Italy. (1988) (33)
Acute upper gastrointestinal bleeding in patients with AIDS: a relatively uncommon condition associated with reduced survival. (1991) (33)
Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients (2005) (33)
Opportunistic infections of the esophagus not responding to oral systemic antifungals in patients with AIDS: their frequency and treatment. (1991) (32)
The Binding Subunit of Pertussis Toxin Inhibits HIV Replication in Human Macrophages and Virus Expression in Chronically Infected Promonocytic U1 Cells1 (2001) (32)
Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV‐related thrombocytopenia (1993) (32)
Evaluation of contrast-enhancing brain lesions in AIDS patients by means of Epstein-Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography. (1997) (32)
Recovery of HIV‐related Retroviruses From Italian Patients with AIDS or AIDS‐related Complex and from Asymptomatic At‐Risk Individuals a (1987) (32)
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma (2000) (32)
Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies (2012) (32)
Slow wave sleep and cyclic alternating pattern (CAP) in HIV-infected asymptomatic men. (1995) (32)
Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals (2002) (32)
How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS) (1997) (31)
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial (2018) (31)
Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV‐positive women (1998) (31)
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients (2008) (31)
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. (2007) (31)
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 (2017) (30)
Rapid killing of actinomycin D-treated tumor cells by human monocytes. II. Cytotoxicity is independent of secretion of reactive oxygen intermediates and is suppressed by protease inhibitors. (1985) (30)
Interferon-Alpha Is Effective in the Treatment of HIV-1Related, Severe, Zidovudine-Resistant Thrombocytopenia: A Prospective, Placebo-controlled, Double-Blind Trial (1994) (30)
Immunomodulatory effects of bovine colostrum in human peripheral blood mononuclear cells. (2007) (29)
Immunological status in heroin addicts: effects of methadone maintenance treatment. (1984) (28)
Factors Associated with the Development of Pneumocystis carinii Pneumonia in 5,025 European Patients with AIDS (1995) (28)
Severe abdominal pain in patients with AIDS: frequency, clinical aspects, causes, and outcome. (1994) (28)
Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment. (2004) (28)
Biobanking for COVID-19 research. (2020) (28)
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. (2013) (28)
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. (2007) (27)
Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56bright subset (2010) (27)
Low incidence of bleeding from HIV‐related thrombocytopenia in drug addicts and hemophiliacs: Implications for therapeutic strategies (1990) (27)
Cyclosporin A in combination with HAART in primary HIV-1 infection. (2000) (27)
Mother-to-child transmission of TT virus: sequence analysis of non-coding region of TT virus in infected mother-infant pairs (2002) (27)
Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. (1999) (27)
Point-of-care testing for HCV infection: recent advances and implications for alternative screening. (2014) (27)
Identification and Structural Characterization of Novel Genetic Elements in the HIV-1 V3 Loop Regulating Coreceptor Usage (2011) (27)
Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3 (2012) (27)
Increased plasma levels of the C-C chemokine RANTES in patients with primary HIV-1 infection. (1997) (27)
An alternative to steroids for prevention of respiratory distress syndrome (RDS): multicenter controlled study to compare ambroxol and betamethasone (1987) (27)
Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. (2006) (26)
Detection of DNA of Lymphotropic Herpesviruses in Plasma of Human Immunodeficiency Virus-Infected Patients: Frequency and Clinical Significance (2002) (26)
Naive HIV/HCV-Coinfected Patients Have Higher Intrahepatic Pro-Inflammatory Cytokines than Coinfected Patients Treated with Antiretroviral Therapy (2005) (26)
Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations (2006) (26)
Diagnostic accuracy and predictive value of 201T1 SPET for the differential diagnosis of cerebral lesions in AIDS patients. (1997) (26)
Number of daily pills, dosing schedule, self‐reported adherence and health status in 2010: a large cross‐sectional study of HIV‐infected patients on antiretroviral therapy (2013) (26)
Lopinavir/ritonavir + tenofovir Dual Therapy versus Lopinavir/ritonavir-Based Triple Therapy in HIV-Infected Antiretroviral Naïve Subjects: The Kalead Study (2010) (26)
NF-κB Modulates Sensitivity to Apoptosis, Proinflammatory and Migratory Potential in Short- versus Long-Term Cultured Human γδ Lymphocytes (2008) (26)
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. (2015) (26)
Human herpesvirus 6 in cerebrospinal fluid of patients infected with HIV: frequency and clinical significance (1999) (25)
Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. (2009) (25)
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results (2014) (25)
Screening of HIV-1 Isolates by Reverse Heteroduplex Mobility Assay and Identification of Non-B Subtypes in Italy (2004) (25)
Augmentation of monocyte chemotaxis by 1 alpha,25-dihydroxyvitamin D3. Stimulation of defective migration of AIDS patients. (1990) (25)
Otoneurological findings in human immunodeficiency virus positive patients (2008) (25)
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. (2005) (24)
Detection of rifampin resistance by single-strand conformation polymorphism analysis of cerebrospinal fluid of patients with tuberculosis of the central nervous system (1997) (24)
Understanding the dynamics of the HIV epidemic among Italian intravenous drug users: a cross-sectional versus a longitudinal approach. (1994) (24)
Effect of L-acetylcarnitine on body composition in HIV-related lipodystrophy. (2009) (24)
INOSIPLEX IN RECURRENT HERPES SIMPLEX INFECTIONS (1982) (24)
Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV‐infected patients (2011) (24)
Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for european patients with acquired immunodeficiency syndrome (1995) (23)
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study (2018) (23)
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy (2014) (23)
In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients. (2005) (23)
Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection (2013) (23)
An In-House RD1-Based Enzyme-Linked Immunospot-Gamma Interferon Assay Instead of the Tuberculin Skin Test for Diagnosis of Latent Mycobacterium tuberculosis Infection (2006) (23)
Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir (2007) (23)
The thalidomide analogue CC‐3052 inhibits HIV‐1 and tumour necrosis factor‐alpha (TNF‐α) expression in acutely and chronically infected cells in vitro (2000) (22)
Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). (2019) (22)
Isolation of spindle-shaped cell populations from primary cultures of Kaposi's sarcoma of different stage. (1996) (22)
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. (2011) (22)
Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort. (1997) (22)
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. (2011) (22)
Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study (2008) (22)
Clinical and immunological aspects of HIV infection in drug addicts. (1989) (22)
HIV-1 AND HIV-2 INFECTIONS IN ITALIAN AIDS/ ARC PATIENTS (1987) (22)
Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the human immunodeficiency virus. (1995) (21)
The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction (2003) (21)
A Mobile Application for Exercise Intervention in People Living with HIV. (2020) (21)
Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients. (1993) (21)
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus (2018) (21)
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus (2018) (21)
Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group. (2000) (21)
The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. (2006) (21)
Influence of gender, age, and transmission category on the progression from HIV seroconversion to AIDS. (1992) (21)
Mediator release in cerebrospinal fluid of human immunodeficiency virus-positive patients with central nervous system involvement (1992) (21)
Chronic granulomatous disease (2004) (20)
HIV seroprevalence among 304 female prostitutes from four Italian towns. (1989) (20)
Offer of rapid testing and alternative biological samples as practical tools to implement HIV screening programs. (2009) (20)
Detection of Pneumocystis carinii and Characterization of Mutations Associated with Sulfa Resistance in Bronchoalveolar Lavage Samples from Human Immunodeficiency Virus-Infected Subjects (2003) (20)
A simplified flow cytometry method of CD4 and CD8 cell counting based on thermoresistant reagents: Implications for large scale monitoring of HIV‐infected patients in resource‐limited settings (2005) (20)
Comparison of Three Nucleic Acid Amplification Assays of Cerebrospinal Fluid for Diagnosis of Cytomegalovirus Encephalitis (2001) (20)
Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. (2018) (20)
The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen (2003) (20)
Tumor necrosis factor-alpha drives HIV-1 replication in U937 cell clones and upregulates CXCR4. (2001) (20)
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. (1996) (19)
Rheumatoid factors and circulating immune complexes in HIV-infected individuals. (1991) (19)
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. (2013) (19)
In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. (2003) (19)
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women (2003) (19)
Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: a prospective open study. (1994) (19)
Acute pancreatitis during primary HIV-1 infection. (1997) (19)
Idiopathic chronic fatigue and chronic fatigue syndrome: a comparison of two case-definitions. (1999) (19)
Diagnosis of toxoplasmic encephalitis in HIV-infected patients. (1997) (19)
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy (2010) (19)
Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial (2000) (19)
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961) (2010) (19)
In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/late simian virus 40 factor. (1999) (19)
Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study. (1995) (19)
Potential role of immune modulation in the effective long-term control of HIV-1 infection. (2002) (18)
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. (2007) (18)
First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006) (2007) (18)
Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects. (1997) (18)
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy (2013) (18)
Phenotype of intramyocardial leukocytic infiltrates in acquired immunodeficiency syndrome (AIDS): a postmortem immunohistochemical study in 34 consecutive cases. (1991) (18)
Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain (2001) (17)
Hodgkin'S Disease in Association with Acquired Immunodeficiency Syndrome (Aids): A Report on 36 Patients (1989) (17)
Bictegravir (2018) (17)
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI (2017) (17)
Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals. (2002) (17)
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. (2012) (17)
Stability of hepatitis C virus (HCV) RNA levels among interferon‐naïve HIV/HCV‐coinfected individuals treated with combination antiretroviral therapy (2013) (17)
Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial (1996) (17)
Immunologic markers of AIDS progression: consistency across five HIV‐infected cohorts Multicohort Analysis Project Workshop. Part I (1994) (17)
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV‐1 infected patients failing HAART (2008) (17)
Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance. (2010) (17)
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males (2017) (16)
Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. (2012) (16)
Double‐edged effect of Vγ9/Vδ2 T lymphocytes on viral expression in an in vitro model of HIV‐1/mycobacteria co‐infection (2003) (16)
Oligoclonai IgG bands in cerebrospinal fluid and serum during asymptomatic human immunodeficiency virus infection (1988) (16)
Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program (2012) (16)
Preliminary clinical experiences with the use of immunomodulators in burns. (1983) (16)
GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. (2005) (16)
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy (2018) (16)
Real-Time PCR Assay for Clinical Management of Human Immunodeficiency Virus-Infected Patients with Visceral Leishmaniasis (2004) (16)
HIV‐1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy (2008) (16)
Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C. (2016) (16)
Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults (2011) (16)
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. (2006) (16)
Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects (2009) (16)
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136) * (2009) (16)
Retrospective Study On The Outcomes Of Two-drugs Regimens Based On Dolutegravir Plus One Reverse Transcriptase Inhibitor In Virologically Suppressed, HIV-Infected Patients. (2020) (16)
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. (2015) (15)
β-Endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects (1994) (15)
Relation Between CD4 Cell Counts and HIV RNA Levels at Onset of Opportunistic Infections (2001) (15)
Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients. (2016) (15)
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population. (2019) (15)
Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96 (2011) (15)
Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. (2003) (15)
HTLV seroreactivity in Italian intravenous drug addicts is primarily due to HTLV-II infection. (1991) (15)
Disseminated rhodococcus equi infection in HIV infection despite highly active antiretroviral therapy (2011) (15)
Expression and Activation of a C-Terminal Truncated Isoform of STAT5 (STAT5Δ) Following Interleukin 2 Administration or AZT Monotherapy in HIV-Infected Individuals (2001) (15)
Comparison of an in-house and a commercial RD1-based ELISPOT-IFN-gamma assay for the diagnosis of Mycobacterium tuberculosis infection. (2006) (15)
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. (2015) (15)
A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine (1991) (15)
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. (2011) (15)
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. (2017) (15)
CCR2 polymorphism and HIV disease. Swiss HIV Cohort. (1998) (15)
Acute self-limiting hepatitis C after possible sexual exposure: sequence analysis of the E-2 region of the infected patient and sexual partner. (2001) (15)
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. (2017) (15)
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting (2013) (15)
Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression. (2007) (15)
Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption (2010) (14)
Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. (1996) (14)
Long‐term treatment with zidovudine in patients with human immunodeficiency virus (HIV)‐associated thrombocytopenia: Modes of response and correlation with markers of HIV replication (1993) (14)
Central Nervous System HIV Infection in “Less-Drug Regimen” Antiretroviral Therapy Simplification Strategies (2014) (14)
CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains, and disease progression. (2000) (14)
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. (2008) (14)
Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results. (1985) (14)
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2 (2017) (14)
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients (2005) (14)
Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. (2002) (14)
Characterization of AIDS-associated tumors in Italy: report of 435 cases of an IVDA-based series. (1990) (14)
The Appealing Story of HIV Entry Inhibitors (2012) (14)
Direct Detection of Helicobacter pylori Mutations Associated with Macrolide Resistance in Gastric Biopsy Material Taken from Human Immunodeficiency Virus-Infected Subjects (2002) (14)
Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. (2003) (14)
Darunavir for the treatment of HIV infection (2018) (14)
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection (2011) (14)
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy (2015) (14)
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens (2012) (14)
Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients (2005) (14)
Cytokines in the acquired immunodeficiency syndrome and other infectious diseases (1995) (14)
Dual role of TNF‐α in NK / LAK cell‐mediated lysis of chronically HIV‐infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell‐mediated lysis (1999) (14)
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy. (1987) (14)
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. (2019) (13)
Effects of hydroxyurea on T cell count changes during primary HIV infection. (2000) (13)
NF-kappa B modulates sensitivity to apoptosis, proinflammatory and migratory potential in short- versus long-term cultured human gamma delta lymphocytes. (2008) (13)
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients (2008) (13)
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients (2003) (13)
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial. (2015) (13)
Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. (2017) (13)
Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy (2009) (13)
Ability of different lopinavir genotypic inhibitory quotients to predict 48‐week virological response in highly treatment‐experienced HIV‐infected patients receiving lopinavir/ritonavir (2006) (13)
Cost-Effectiveness of Enfuvirtide for Treatment-Experienced Patients with HIV in Italy (2005) (13)
Moderate aerobic exercise (brisk walking) increases bone density in cART‐treated persons (2012) (13)
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection. (1989) (13)
Oesophagobronchial fistula caused by varicella zoster virus in a patient with AIDS: a unique case. (2002) (13)
The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic-Clinical Management of HIV-1 Infected Persons (2018) (12)
92 Final week-72 results of the aids pegasys ribavirin international co-infection trial (APRICOT): A randomized, partially blinded, multinational comparative trial of peginterferon ALFA-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) vs interferon ALFA-2A(IFN) (2004) (12)
Enhanced basophil releasability in subjects infected with human immunodeficiency virus. (1990) (12)
Human immunodeficiency virus (HIV) seropositivity in intravenous (IV) drug abusers in three cities of Italy: Possible natural history of HIV infection in IV drug addicts in Italy (1987) (12)
Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. (2013) (12)
Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. (2007) (12)
CD30 ligation differentially affects CXCR4‐dependent HIV‐1 replication and soluble CD30 secretion in non‐Hodgkin cell lines and in γ δ T lymphocytes (2003) (12)
Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets (2015) (12)
Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance (2011) (12)
Diagnosis of cytomegalovirus infection of the nervous system in AIDS by polymerase chain reaction analysis of cerebrospinal fluid. (1995) (12)
Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients: Week 48 Primary Analysis Results From an Ongoing, Multicenter, Randomized, Double-Blind, Phase IIb Trial (2013) (12)
Sequencing antiretroviral drugs for long-lasting suppression of HIV replication. (2005) (12)
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients (2017) (12)
Erratum: Real-Time PCR Assay for Clinical Management of Human Immunodeficiency Virus-Infected Patients with Visceral Leishmaniasis (Journal of Clinical Microbiology (2003) 41, 11 (5080-5084)) (2004) (12)
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption (2011) (12)
Neurobrucellosis with spinal cord abscess of the dorsal tract: a case report. (2002) (11)
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients (2013) (11)
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study (2014) (11)
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. (2020) (11)
Significant link between sCD30 changes and HIV viremia in patients treated with HAART (2006) (11)
Durability of Lopinavir/Ritonavir Monotherapy in Individuals with Viral Load ≦50 Copies/Ml in an Observational Setting (2014) (11)
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group (2013) (11)
Soluble CD30, tumour necrosis factor (TNF)-alpha, and TNF receptors in primary HIV-1 infection: relationship with HIV-1, RNA, clinical outcome and early antiviral therapy. (1997) (11)
Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2. (2002) (11)
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. (2016) (11)
Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine (2008) (11)
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. (2015) (11)
Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: an Italian pilot study in a dental clinic. (2017) (11)
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin (2015) (11)
Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients. (1999) (11)
Experiences in immune reconstitution. The rationale for interleukin-2 administration to HIV-infected individuals. (1997) (11)
Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations (2008) (11)
Efficacy and Safety of atazanavir (ATV) Based HAART in patients switched from a stable boosted/unboosted protease-inhibitor (PI) treatment. The SWAN study (2005) (11)
Raised serum β2 microglobulin levels in different stages of human immunodeficiency virus infection (1988) (11)
Immune recovery and T cell subset analysis during effective treatment with maraviroc. (2012) (11)
TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype (2016) (10)
Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service (2014) (10)
Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTI‐sparing regimen for HIV‐infected naïve patients: 48‐weeks final results (2012) (10)
Cross-sectional study of community serostatus to highlight undiagnosed HIV infections with oral fluid HIV-1/2 rapid test in non-conventional settings. (2013) (10)
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients (2017) (10)
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART (2018) (10)
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic. (2020) (10)
Kappa light chain predominance in serum and cerebrospinal fluid from human immunodeficiency virus type 1 (HIV-1)-infected patients (1991) (10)
HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy (2020) (10)
Non‐invasive fibrosis biomarkers – APRI and Forns – are associated with liver stiffness in HIV‐monoinfected patients receiving antiretroviral drugs (2013) (10)
Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection. (2000) (10)
Acute ataxia coincident with seroconversion for anti-HIV (1991) (10)
Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients (2009) (10)
Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine. (2008) (10)
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. (2012) (10)
The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV (2020) (10)
Mortality of HIV-Infected Patients with or without Cancer: Comparison with the General Population in Italy (2012) (10)
Risk of HIV-1 transmission in heterosexual stable and random couples. The Italian Partner Study. (1997) (10)
Magnitude and Determinants of CD4 Recovery After HAART Resumption After 1 Cycle of Treatment Interruption (2009) (10)
Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. (1995) (10)
Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during the period 1984-1997. (1998) (10)
Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a. (2003) (10)
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. (2011) (10)
Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy (2018) (10)
Shorter Survival of SDF 1-3 ′ A / 3 ′ A Homozygotes Linked to CD 4 + T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection (10)
Pharmacokinetics of Zidovudine in HIV‐Positive Patients with Liver Disease (1994) (10)
Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure (2009) (9)
Detection of hepatitis C virus RNA by methods using phenol-chloroform or silica particles (1995) (9)
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). (2006) (9)
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. (2018) (9)
Mutations in the E2–PePHD region of hepatitis C virus type 1b in patients with hepatocellular carcinoma (2005) (9)
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV (2018) (9)
Malignant tumors in patients with human immunodeficiency virus infection: a report of 580 cases. (1989) (9)
Homeostatic model assessment for insulin resistance index trajectories in HIV‐infected patients treated with different first‐line antiretroviral regimens (2019) (9)
Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases. (2010) (9)
The maraviroc expanded access program — safety and efficacy data from an open-label study (2015) (9)
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. (2006) (9)
O415 Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2NRTIs) in patients with VL <50 c/mL after induction with ATV/r + 2NRTIs: study AI424136 (2008) (9)
Demonstration of antibodies to human T-lymphotropic retrovirus type III in lymphoadenopathy syndrome patients and in individuals at risk for acquired immune deficiency syndrome (AIDS) in Italy. (1986) (9)
Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C. (1997) (9)
CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and in gamma delta T lymphocytes. (2003) (9)
Recombinant Human Growth Hormone (2012) (9)
Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy. (2008) (8)
Milan as possible starting point of LAV/HTLV III epidemic among Italian drug addicts. (1987) (8)
PHAGOCYTE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS (1975) (8)
Analysis of serum and plasma beta chemokines in primary HIV infection (PHI). (2000) (8)
Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users. (1992) (8)
Molecular and phylogenetic characterization of HIV variants in Italian primary HIV infections (PHI): identification of non-B subtype variants. (2002) (8)
Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials (2018) (8)
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients (2017) (8)
Double-edged effect of Vgamma9/Vdelta2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. (2003) (8)
Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters. (2000) (8)
Epidemic HIV-related Kaposi's sarcoma: a retrospective analysis and validation of TIS staging. GICAT. Gruppo Italiano Collaborativo AIDS e Tumori. (1995) (8)
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. (2019) (8)
Parallel Western blot analysis for HIV-1 and HIV-2 antibodies: absence of HIV-2 infection in Italian subjects at risk for AIDS. (1988) (8)
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). (1986) (8)
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection (2017) (8)
Impairment of in vitro natural antibacterial activity in HIV-infected patients. (1988) (8)
Thymostimulin treatment in AIDS-related complex. (1988) (8)
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine. (2014) (8)
Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy. (2007) (8)
Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters (2002) (8)
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. (2008) (8)
Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients (2004) (8)
Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis (2016) (8)
Prolonged course and relapses of acute type A hepatitis. (1984) (7)
Oral CCR5 inhibitors: will they make it through? (2006) (7)
A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection. (2000) (7)
Survival differences for 547 AIDS cases in Milan. (1992) (7)
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (2010) (7)
Malignant lymphoma related to HIV infection in Italy: a report of 46 cases. (1987) (7)
Low levels of LTB4 in cerebrospinal fluid of AIDS patients with cryptococcal meningitis. (1995) (7)
Molecular studies of cerebrospinal fluid in human immunodeficiency virus type 1-associated opportunistic central nervous system diseases--an update. (2002) (7)
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy (2016) (7)
Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. (2014) (7)
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens (2017) (7)
Natural Killer‐Cell Cytotoxicity in HIV‐Positive and HIV‐Negative Patients with and Without Severe Course of Hepatitis B Virus Infection (2005) (7)
Monotherapy with atazanavir as a simplification strategy: results from an observational study. (2012) (7)
The use of circulating cathodic antigen rapid test and serology for diagnosis of active Schistosoma mansoni infection in migrants in Italy, a non-endemic country: a cross sectional study (2017) (7)
Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries? . (2017) (7)
Psychoactive drug use and AIDS. (1990) (7)
Predictors of sustained response to therapy resumption after treatment interruption in HIV‐infected patients failing antiretroviral therapy (2004) (7)
Modeling incidence rate ratio and rate difference: additivity or multiplicativity of human immunodeficiency virus parenteral and sexual transmission among intravenous drug users. Northern Italy Seronegative Drug Addicts Study. (1995) (7)
Hepatitis C virus infection in blood donors with indeterminate results in second‐generation recombinant immunoblot assay (1994) (7)
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial. (2010) (7)
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients (2016) (7)
Highlights on HIV eradication in 2013. (2014) (7)
Granulocyte/monocyte apheresis induces sustained increases in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART. (2002) (7)
LEUCOCYTE FUNCTION AFTER ANTENATAL BETAMETHASONE GIVEN TO PREVENT RESPIRATORY DISTRESS (1977) (7)
Favorable outcome of ex‐vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV‐1 (2007) (7)
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission. (2001) (6)
Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular risk. (2014) (6)
Splenic irradiation versus splenectomy for severe, refractory HIV-related thrombocytopenia: effects on platelet counts and immunological status. (2000) (6)
A step ahead on the HIV collaboratory. (2009) (6)
Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy (2020) (6)
Ex-vivo purging of circulating monocytes results in immunovirologic improvement in partially HAART responder HIV-infected patients. (2000) (6)
Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. (2017) (6)
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study (2018) (6)
Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. (2001) (6)
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients (2017) (6)
HIV SEROCONVERSION RATES IN INTRAVENOUS DRUG ABUSERS FROM NORTHERN ITALY (1989) (6)
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients (2003) (6)
Membrane Expression and Function of Complement Receptors CR1 and CR3 on Neutrophils from HIV‐Infected Subjects: Modulation by rTNF‐α and rGM‐CSF (1992) (6)
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease. (2014) (6)
Detection of resistance to isoniazid by denaturing gradient-gel electrophoresis DNA sequencing in Mycobacterium tuberculosis clinical isolates. (2003) (6)
Risk of AIDS in HIV seroconverters: A comparison between intravenous drug users and homosexual males (1990) (6)
Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinaemia and hepatitis C virus (HCV) infection (1997) (6)
Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group. (1996) (6)
DASABUVIR AND OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: REAL LIFE INTERIM ANALYSIS OF AN ITALIAN MULTICENTRE COMPASSIONATE USE PROGRAM (2016) (6)
Treatment of Recurrent Viral Infectious Diseases by Methisoprinol (1984) (6)
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir (2016) (6)
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression (2018) (6)
Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. (2016) (6)
Epidemic Kaposi's sarcoma in Italy, a country with intravenous drug users as the main group affected by HIV infection. (1991) (6)
Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naï ve Patients: 192 Week Results from STARTMRK (2011) (6)
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. (2007) (6)
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study). (2012) (6)
Attempted treatment of fulminant viral hepatitis with human fibroblast interferon (1985) (6)
Pulmonary candidiasis in a heroin addict: some remarks on its aetiology and pathogenesis. (1985) (6)
Effect of ambroxol on human phagocytic cell function. (1985) (6)
Management of HIV infection after triple class failure. (2013) (6)
CD4+ Cell Restoration at 48 Weeks in the Maraviroc (MVC) Treatment-Naive (TN) MERIT Trial (2008) (5)
AIDS IN AN ITALIAN DRUG ADDICT (1984) (5)
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. (2013) (5)
Characterization of GBV-C infection in HIV-1 infected patients. (2003) (5)
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). (2016) (5)
In vitro modulation of human endothelial cell growth by Kaposi's sarcoma sera. (1990) (5)
In Vivo Treatment with Fusion Inhibitor EnfuvirtideLeads to Increased IL-12 Production by Autologous inVitro Activated Monocytes from HIV-infected Individuals (2009) (5)
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. (1992) (5)
Raltegravir in treatment naïve patients (2009) (5)
An In-House RD 1-Based Enzyme-Linked Immunospot – Gamma Interferon Assay Instead of the Tuberculin Skin Test for Diagnosis of Latent Mycobacterium tuberculosis Infection (2006) (5)
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy (1991) (5)
Viral dynamics and mutations in the pol gene during primary HIV-1 infection. (2000) (5)
Early production of HIV-1 neutralising antibodies in patients following highly active antiretroviral treatment (HAART) during primary HIV infection. (2000) (5)
Lack of immune recovery in HIV/Leishmania co-infection treated with human recombinant IL-2. (2007) (5)
Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile (2007) (5)
Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe (2018) (5)
Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART. (2016) (5)
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens. (2013) (5)
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients (2017) (5)
Impact of HAART on liver histology of HIV/HCV coinfected patients. (2003) (5)
[Solid tumors associated with HIV infection]. (1993) (5)
A randomized controlled study for the evaluation of the activity of a triple combination of zidovudine, thymosin-alpha(1) and interferon-alpha in HIV-infected individuals with CD4 counts between 200 and 500 cells/mm(3) (1998) (5)
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. (2015) (5)
Human Immunodeficiency Virus gp120 and p24 Oligoclonal Antibody in Acquired Immunodeficiency Syndrome Cerebrospinal Fluid and Sera a (1988) (5)
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? (2019) (4)
Hepatitis B surface antigen clearance and appearance of antibodies against hepatitis B surface antigen after treatment with recombinant interleukin 2 in a human immunodeficiency virus-infected patient. (2000) (4)
T-lymphocyte subsets and delayed type hypersensitivity as classification parameters for HIV infection among drug-addicts. (1988) (4)
Evolution of the E2 region of hepatitis C virus in an infant infected by mother‐to‐infant transmission (2001) (4)
Lymph node finding in drug abusers. (1984) (4)
Residual viremia in HIV-infected patients who continue a 2-drug or switch to a 3-drug integrase strand transfer inhibitor-based regimen. (2021) (4)
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. (2014) (4)
Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus. (2013) (4)
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load (2018) (4)
Transitory expansion of a CD3+TcR γ/δ+CD16+ lymphocytic population in two patients with advanced human immunodeficiency virus infection and high levels of natural killer activity (1994) (4)
Cost‐effectiveness evaluation of initial HAART regimens for managing HIV‐infected patients according to real clinical practice (2012) (4)
Epidemic Kaposi's sarcoma in Italy, a country with intravenous drug abusers as the major group at risk for AIDS: report of 60 cases. (1989) (4)
Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor. (2001) (4)
Metabolic Profiles and Body Composition Changes in Treatment-Naï ve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 48-Week Data (2009) (4)
Ex vivo modulation of RANTES and sCD30 by proinflammatory stimuli in HIV-seropositive and -negative individuals. (2000) (4)
Experiences with immunomodulant agents in HIV infections. (1987) (4)
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study (2019) (4)
Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and β2-microglobulin are not adequate to estimate time of HIV infection Multicohort Analysis Project Workshop. Part II (1994) (4)
Immunovirological improvement in partially HAART responder HIV‐infected patients by monocyte adsorption apheresis (2001) (4)
Efficacy of atazanavir (ATV) based HAART in patients switched from a stable PI or boosted PI (PI/r) treatment. Planned week 24 analysis of a phase IIIb 48 week multicenter, open-label, randomized, prospective trial. The SWAN study (2005) (4)
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology. (2014) (4)
NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B (2017) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Safety and effi cacy of the peptide-based therapeutic vaccine for HIV-1 , Vacc-4 x : a phase 2 randomised , double-blind , placebo-controlled trial (2014) (4)
Leishmaniasis Virus-Infected Patients with Visceral Management of Human Immunodeficiency Real-Time PCR Assay for Clinical (2003) (4)
Susac’s syndrome as HIV-associated immune reconstitution inflammatory syndrome (2013) (4)
In vivo evidence that the cannabinoid receptor 2–63 RR variant is associated with the acquisition and/or expansion of HIV infection (2018) (4)
The effect of HAART on humoral immune response in primary HIV-1 infected patients. (2002) (4)
235 Enhanced IgE-mediated basophil releasability in patients with HIV infection (1988) (4)
HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy (2016) (3)
IUD use and man to woman sexual transmission of HIV-1. (1994) (3)
Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome (2004) (3)
A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies. (2004) (3)
Letters to the editor Vulvar Kaposi's sarcoma. A case report (1991) (3)
Structural skull defects in type IV Ehlers‐Danlos syndrome (1984) (3)
Role of PMN's candidicidal activity in the pathogenesis of AIDS-related systemic candidiases. (1987) (3)
Diagnosis of Virus‐associated Opportunistic Diseases of the Central Nervous System in Patients with HIV Infection by Polymerase Chain Reaction on Cerebrospinal Fluid (1994) (3)
Kaposi's sarcoma in Italy, a country with intravenous drug users as the main group affected by HIV infection. (1991) (3)
Opportunistic infections in AIDS patients in Milan. (1987) (3)
Management Strategies for Herpesvirus Infections of the CNS (2000) (3)
Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL-2 administration (2003) (3)
Gender, relationship length and the risk of heterosexual HIV transmission (1989) (3)
Safety and tolerability of etravirine (ETR; TMC125) in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results (2008) (3)
Managing Failure to Antiretroviral Drugs in HIV-1-Infected Patients (2003) (3)
Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression (2014) (3)
Hodgkin's Disease in 50 Intravenous Drug Users with HIV-Infection. (1991) (3)
HIV-1 DNA and RNA kinetics in primary HIV infection. (2002) (3)
Inter- and intra-individual variability of enfuvirtide (ENF) plasma trough concentrations (Ctrough) in the clinical setting (2004) (3)
Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients. (1996) (3)
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman. (2014) (3)
Influenza A (H1N1) virus infection in Intensive Care Unit: the point of view of the infectious diseases consultant. (2009) (3)
Brachial paresis complicating acute non-A, non-B hepatitis. (1984) (3)
Follicle lysis in lymph nodes from homosexual men. (1986) (3)
Follicle lysis in lymph nodes from homosexual men [letter] (1986) (3)
Immunohistochemical reactivity of anti-LAV p18 monoclonal antibody in lymph nodes from PGL and AIDS patients. (1985) (3)
Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report. (2002) (3)
Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study (2016) (3)
Reverse Transcriptase Mutations in HIV-1 Infected Patients Treated with Two Nucleoside Analogues: The Smart Study (2002) (3)
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer‐free, HIV‐1–infected patients (2013) (3)
Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death (2014) (3)
Relapse of Symptomatic Cerebrospinal Fluid HIV Escape (2020) (3)
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. (2018) (3)
Selective enrichment of CD30-expressing cells within the blast region of lymphocytes from patients with primary HIV infection (PHI). (2002) (3)
Immunological Basis for IgE Hyper-Production in Enfuvirtide-Treated HIV- Positive Patients (2006) (3)
The introduction of the fusion inhibitors in the HAART-regimens. (2004) (3)
Lack of reduction of thymidine kinase activity in stavudine-treated HIV-infected patients. (2004) (3)
Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. (1995) (3)
Heterogeneity in exposed uninfected individuals. (1997) (3)
Raised serum beta 2 microglobulin levels in different stages of human immunodeficiency virus infection. (1988) (2)
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial (2015) (2)
Risk of human immunodeficiency virus infection in multiple transfused patients (1987) (2)
IgG and C3 receptors on polymorphonuclear leukocytes in phagocytosis. Role of C3-receptors in the attachment and ingestion phases. (1977) (2)
P0909 : Analysis of natural resistance profile to NS5A replication complex inhibitors in different Hepatitis C genotypes (2015) (2)
Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine (2012) (2)
Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5 Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals. (2001) (2)
Modifications of leucocyte function in visceral leishmaniasis. (1981) (2)
Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection (2014) (2)
Albendazole in the treatment of cystic hydatid disease. (1986) (2)
Clinical and epidemiological aspects of the first 50 cases of AIDS in Milan. (1986) (2)
Humoral immune responses in human loaiasis. (1982) (2)
Outbreak of persistent, unexplained, generalized lymphadenopathy with immunological abnormalities in drug addicts in Milan (1984) (2)
Incidence of ischemic cardiovascular events in the maraviroc clinical development program (2010) (2)
Increase of OKT4+ cells during treatment with thymostimulin in parenteral drug addicts with persistent generalized lymphadenopathy. (1986) (2)
The rationale for a study on HIV-1 reverse transcriptase mutations and outcome of antiretroviral therapy with two nucleoside analogs. (1999) (2)
HIV-1 Tropism Test Evaluation: Assessment and Clinical Implications (2014) (2)
Predictors of lack of serological response to syphilis treatment in HIV-infected subjects (2014) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
The role of superoxide anion generation in antibody-dependent polymorphonuclear leukocyte-mediated cytotoxicity. (1979) (2)
Decreased chloroquine sensitivity of Plasmodium falciparum in two Italian travellers from Madagascar. (1984) (2)
Increased hyperglycaemia during cotreatment with pentamidine and corticosteroids in AIDS patients. (1997) (2)
Raltegravir Demonstrates Durable Efficacy Through 96 Weeks: Results from STARTMRK, A Phase III Study of Raltegravir-b ased vs. Efavirenz-based Therapy in Treatment-Naï (2009) (2)
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study (2017) (2)
Risk behaviour and HTLV-1 seropositivity in injecting drug users. (1990) (2)
Early diagnosis and retention in care of HIV-infected patients through rapid salivary testing: a test-and-treat fast track pilot study. (2015) (2)
Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen. (2005) (2)
Effects of endurance exercise training on metabolic and inflammatory parameters in HIV-1-infected patients with secondary lipodystrophy and diabetes (2010) (2)
Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals. (2004) (2)
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. (2014) (2)
Epidemic of LAV/HTLV III infection in drug addicts in milan: Serological survey and clinical follow-up (1985) (2)
Improvement of CXCR3 ligand CXCL11/I-TAC measurement in human plasma and serum. (2009) (2)
Effectiveness of Simeprevir Treatment for Hepatitis C in Real Practice: Preliminary Results from the Stily Italian Observational Study (2016) (2)
Adherence, quality of life and number of daily pills in a large cross-sectional study (2010) (2)
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study (2011) (2)
Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program (2010) (2)
Italian multicentre study of didanosine compassionate use in advanced HIV infection (1997) (2)
Transitory expansion of a CD3+TcR gamma/delta+CD16+ lymphocytic population in two patients with advanced human immunodeficiency virus infection and high levels of natural killer activity. (1994) (2)
Primary HIV infection: molecular approaches in diagnosis and monitoring. (2000) (2)
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir (2010) (2)
IMMUNOLOGICAL MARKER PATHS FOR SEROCONVERSION - SINGLE DETERMINATIONS OF IMMUNOGLOBULIN-A AND BETA(2)-MICROGLOBULIN ARE NOT ADEQUATE TO ESTIMATE TIME OF HIV-INFECTION (1994) (2)
Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with AIDS-related tumors and chemotherapy-induced bone-marrow suppression. (1990) (2)
Nitric Oxide Production in HIV-1 Infected Patients Receiving Intermittent Cycles of Interleukin-2 and Antiretrovirals (2004) (1)
Non-Hodgkin’s Lymphomas in Patients with AIDS (1990) (1)
Pentamidine for primary prevention of Pneumocystis carinii pneumonia (1991) (1)
Impact of antiretroviral dosing frequency and daily pill burden on virological success rates in patients of the ICoNA cohort starting their first ART (2012) (1)
Study on mutations and antiretroviral therapy (SMART): preliminary results. (1999) (1)
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin. (2015) (1)
3OD – Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherence (2008) (1)
The role of host immunity in the control of HIV infection: from theory to diagnostic and therapeutic intervention. (2004) (1)
Diagnostic and prognostic significance of β2-microglobulin during HIV infection (1990) (1)
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study). (2020) (1)
Chronic granulomatous disease in a 23-year-old female. (1986) (1)
First Case of Transfusion‐Associated AIDS in Italy: A Single Transfusion with a 51‐month Latency Period (1987) (1)
Epidemiology of toxoplasma encephalitis and need for primary prophylaxis among AIDS patients in northern Italy. (1990) (1)
Polymorphonuclear leucocytes functions from premature infants after prevention of respiratory distress syndrome with betamethasone and ambroxol. (1984) (1)
Tipranavir/ritonavir (TPV/r) Demonstrates Superior Treatment Response to Lopinavir/r (LPV/r), Amprenavir/r (APV/r), and Saquinavir/r (SQV/r) in PI-experienced Patients From the TPV RESIST-1 and RESIST-2 Trials (2005) (1)
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study. (2016) (1)
ABC of AIDS: Treatment of infections and antiviral agents (1987) (1)
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. (1997) (1)
Rate and predictive factors of spontaneous hepatitis C virus clearance after acute infection in human immunodeficiency virus-positive subjects (2017) (1)
Polymorphonuclear leucocyte function during acute viral hepatitis. (1984) (1)
Immortal time bias: authors' reply. (2015) (1)
Tipranavir/ritonavir (TPV/r) Demonstrates Superior Treatment Response to Lopinavir/r (LPV/r), Amprenavir/r (APV/r), and Saquinavir/r (SQV/r) in PI-experienced Patients From the TPV RESIST-1 and RESIST-2 Trials (2005) (1)
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study (2014) (1)
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting (2010) (1)
Hepatitis C virus infection in HIV-infected long term non progressors (LTNPS) (2003) (1)
1211 AMINO ACID CHANGE IN THE POSITIONS ASSOCIATED WITH PROTEASE INHIBITORS RESISTANCE IS LESS FREQUENT IN GENOTYPE 3 THAN IN GENOTYPE 1 HCV NATURAL STRAIN (2013) (1)
Virological patterns of hepatitis C virus in chronic hepatitis C with biochemical sustained response to interferon therapy (1996) (1)
Are artemisinin-based combination therapies effective against Plasmodium malariae ? (2013) (1)
Cross–sectional and retrospective questionnaire-trial to evaluate exercise habits in a sample of HIV–infected individuals with type 2 diabetes mellitus (2005) (1)
Vulvar Kaposi's sarcoma. A case report. (1991) (1)
Feasibility of a Stem Cell Gene Therapy Approach with Nonmyeloablative Conditioning in Patients with HIV-1 Infection. (2004) (1)
INOSIPLEX IN RECURRENT HERPES SIMPLEX INFECTION (1982) (1)
Diagnostic and prognostic significance of beta 2-microglobulin during HIV infection. (1990) (1)
[Demonstration of a granulocyte defect in aged persons correlated with the presence of autoantibodies]. (1976) (1)
HEFFICON: HIV Effectiveness Italian Conference. (2015) (1)
Serious Fatal and Non-Fatal Non-AIDS D efining Illnesses (non-ADI) in Europe (2009) (1)
A Randomized Controlled Study for the Evaluation of the Activity of a Triple Combination of Zidovudine, Thymosin-α1 and Interferon-α in HIV-Infected Individuals with CD4 Counts between 200 and 500 cells/mm3 (1998) (1)
HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults (2015) (1)
Is Maraviroc a substrate for SLCO1B1 (2009) (1)
Primary prevention of Pneumocystis carinii pneumonia by inhalation of pentamidine. Preliminary results from a placebo-controlled randomized trial. Swiss Group for Clinical Studies on AIDS. (1990) (1)
Polymorphonuclear leukocyte function in burned patients: effect of isoprinosine. (1983) (1)
Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin‐2 (2010) (1)
Human immunodeficiency virus (HIV) gp120 and p24 oligoclonal antibody (ab) in acquired immunodeficiency syndrome (AIDS) cerebrospinal fluid (CSF) and sera (1987) (1)
Negative regulation of HIV-1 expression by the natural isoform C-terminus truncated STAT5 (STAT5Δ) (2006) (1)
Prevalence of type 2 diabetes mellitus and its predictive factors in Italy: a comparison between HIV-infected and uninfected subjects (2010) (1)
stARTing cART now! HIV treatment Italian Guidelines Update Dec. 2014. (2015) (1)
Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients. (2008) (1)
A trial with ribavirin in patients with AIDS or AIDS-related complex. (1989) (1)
IMMUNOLOGICAL MARKERS OF AIDS PROGRESSION - CONSISTENCY ACROSS 5 HIV-INFECTED COHORTS (1994) (1)
Cost Effectiveness Analysis of The Use of Daclatasvir for the Treatment of Hepatitis C Virus (Hcv) Genotypes 3 in Cirrhotic Patients Within the Italian National Health Service. (2015) (1)
Viro-immunological outcomes after thirteen-valent pneumococcal vaccination in HIV-1 infected subjects on stable virological suppression. (2019) (1)
HIV protease inhibitors: Present and future (2011) (1)
Defect of leukocyte functions and circulating immune complexes in visceral leishmaniasis. (1985) (1)
Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine (2012) (1)
Prophylactic and therapeutic phase I trials with the active Tat protein vaccine: results of the interim analysis (2006) (1)
Impact of lamivudine monotherapy in failing patients with multidrug‐resistant HIV: final 48 weeks results (MONO‐AIFA FARM7PAZS3) (2012) (1)
556 Mutations in the NS3 protease domain of HCV in HIV/HCV coinfected patients under antiretroviral therapy (ART) (2006) (1)
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study. (2016) (1)
Short- versus Long-Term Cultured Human Proinflammatory and Migratory Potential in B Modulates Sensitivity to Apoptosis, κ NF- (2013) (0)
Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients. (2006) (0)
Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum] (2022) (0)
Brisk walking increases bone mineral density in cART-patients? (2013) (0)
Prevalence of wild-type in interferon sensitivity determining region (ISDR) of hepatitis C virus in HIV-1 positive patients infected with HCV genotype 3A non responders to anti-HCV treatment (2002) (0)
Impact of HIV subtype on response and resistance in antiretroviral-naïve adults comparing treatment with once daily versus twice daily ritonavir boosted fosamprenavir in combination with Abacavir/Lamivudine (2011) (0)
Burnout mediates the relationship between coping strategies and self-perceived health in healthcare providers working with HIV/AIDS patients (2021) (0)
Attitudes and opinions toward HIV infection of 1,008 participants to the Vth International Conference on AIDS Montreal, 4-9 June 1989. (1990) (0)
[Respiratory complications in 44 patients with acquired immunodeficiency syndrome]. (1991) (0)
Progression of liver histological lesions in HIV/HCV coinfection (2008) (0)
Risk of HIV infection in recipients of blood and blood products. (1987) (0)
Efficacy and Safety of Fosamprenavir + Ritonavir (FPV/r) 700mg/100mg Twice Daily (BID) Versus FPV/r 1400mg/100mg Once Daily (QD) with ABC/3TC QD over 24 Weeks (2008) (0)
Persistent generalized lymphadenopathy in drug addicts: immunological studies. (1986) (0)
Ophthalmic Manifestations in HIV Positive Patients: Evaluation of 286 Consecutive Patients in One Year (2005) (0)
Ascending paralysis in AIDS patients: Guillain Barrè syndrome or cytomegalovirus (CMV) polyradiculopaty? (1996) (0)
Antibodies to HLA class I antigens in seronegative individuals at risk for HIV exposure (1994) (0)
Detection of clarithromycin resistance in Helicobacter pylori infected patients (2001) (0)
SAT-404-Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients (2019) (0)
Therapy with high dosed immunoglobulins in patients with correlated HIV and thrombocytopenia (1987) (0)
Primary HIV infection: therapeutic strategies. (1997) (0)
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (2021) (0)
Hepatitis C virus-RNA decay with direct acting antivirals in human immunodeficiency virus/hepatitis C virus coinfected patients (2017) (0)
Thallium-201 SPECT accuracy to detect brain lymphomas in AIDS patients using different uptake indexes (1996) (0)
15.A Clinical Study on Safety and Immunovirological Efficacy of Granulocyte and Monocyte Apheresis with Adacolumn in HIV Infected Patients who Partially Responded to HAART (2001) (0)
PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING (2009) (0)
[Opportunistic infections and tumors in AIDS]. (1991) (0)
Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV (2021) (0)
[Deficits of granulocytic function in pathology of adult and pediatric ages. (Personal observations and review of the literature)]. (1979) (0)
Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors. (2017) (0)
[570] MUTATIONS IN THE NATURAL STRAINS OF NS3 PROTEASE DOMAIN THAT CONFER RESISTANCE TO ANTI-HCV PROTEASE INHIBITORS IN HIV/HCV COINFECTED PATIENTS (2007) (0)
Cross–sectional and retrospective questionnaire-trial to evaluate exercise habits in a sample of HIV–infected individuals with type 2 diabetes mellitus (2006) (0)
[Granulocyte function in patients in the acute phase of severe diseases]. (1981) (0)
Early diagnosis and retention in care of HIV-infected patients through rapid salivary testing: a test-and-treat fast track pilot study. (2016) (0)
Unusual parenteral HIV transmission (1991) (0)
PIN23 To Assess or Not To Assess: That is the Question! Budget, Ethical and Decisional Impact assessment in HIV: Lombardy Region's Molo Project (2011) (0)
Long-Term Response in Patients Receiving HAART Including Nelfinavir: Experience from Two Italian Centers (2002) (0)
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice (2022) (0)
Comparison of clinical findings of 148 HIV-related non-Hodgkin's lymphomas among intravenous drug abusers and homosexual men in Italy and France. (1989) (0)
Risk of developing AIDS in newly seropositive intravenous drug abusers. (1989) (0)
Real-Life Experience of Daa-Based Regimens Plus Ribavirin in Cirrhotic Patients Coinfected with HCV and HIV-1 (2016) (0)
[Effect of ambroxol on the activity of phagocytic cells in vitro]. (1984) (0)
[The sexual transmission of the acquired immunodeficiency virus: the reasons for greater male-to-female than female-to-male transmission efficiency]. (1994) (0)
Use of central venous catheterization for AIDS patients. (1991) (0)
Human and chicken antibodies to CCR5-ECL1 block mucosal and systemic HIV infection (2006) (0)
Association Between the Presence of CCR5-specific Antibodies and Long Term Non Progression (2005) (0)
Does cyclosporin A affect CCR5 and CXCR4 expression in primary HIV‐1‐infected patients? (2007) (0)
seronegative subjects CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed (2012) (0)
A 12-week program of moderate intensity exercise reduces plasma myostatin in HIV-infected subjects (2013) (0)
Original article Predicting the magnitude of short-term CD4 + T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy (2010) (0)
Exercise ECG for coronary artery disease screening in people living with HIV (2021) (0)
Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis (2010) (0)
P0588 : Immune response to hepatitis B vaccination in HIV infected individuals with isolated antibodies to HBV core antigen (2015) (0)
HIV-1 provirus detection by PCR in seronegative drug addicts (1993) (0)
Virus 40 Factor and Leader Binding Protein-1/Late Simian of the Transcription Factors Ying-Yang-1 Down-Modulates the Binding and Expression to Individuals Infected by HIV In Vivo Administration of Recombinant IL-2 (1999) (0)
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response. (2017) (0)
Non Progressors: a possible protective effect against disease progression Long lasting CCR5 internalization by antibodies in a subset of Long Term (2013) (0)
Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine. (1997) (0)
Epidemiological aspects of human immunodeficiency virus infection in Milan. (1987) (0)
AP-1 mediated-CXCL8 expression up-regulates HIV infection and virus replication (2002) (0)
Pharmacokinetic of doxorubicin during chemotherapy in HIV patients affected by Hodgkin disease and Non- Hodgkin’s Lymphoma: the PKCT study (2014) (0)
A comparison of DNA enzyme immunoassay and radioactive probe hybridization for the detection of hepatitis C virus amplification products (1993) (0)
Risk of HIV-related diseases in heterosexuals importing infection from Zaire (1988) (0)
Down-Modulate Surface CCR5 In Vivo and Partners of HIV-Seropositive Individuals CCR5-Reactive Antibodies in Seronegative (2000) (0)
6 The NS3 protease gene of HCV is highly conserved between isolates of the same genotype (2003) (0)
[Pathology of HTLV III/LAV virus infection]. (1986) (0)
Tambussi Immunotherapy in HIV disease : recent developments and future directions (2009) (0)
P.411 The impact of age on sustained virological response in genotype 1 HIV-HCV co-infected patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): AIDS PEGASYS ribavirin co-infection trial (APRICOT) (2006) (0)
[The immunofluorescence technique detecting antibody-coated bacteria for diagnosis of site of UTI (author's transl)]. (1976) (0)
Genotypic resistance tests for the clinical management of patients with primary HIV infection. (2003) (0)
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection. (2020) (0)
4. Immunological Improvement Following Adacolumn Granulocyte and Monocyte Adsorption Apheresis in Patients with Low CD4^+ T Cells during Anti-HIV Drug Therapy (2002) (0)
Safety and eﬃ cacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial (2014) (0)
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL—authors' response (2012) (0)
Immunotherapy of HIV Infection: Dendritic Cells as Targets and Tools (2007) (0)
P224 DIFFERENT PROFILE OF NATURAL RESISTANCE TO NS3 PROTEASE INHIBITORS IN HEPATITIS C SUBTYPES 1A AND 1C (2014) (0)
Detection of clarithromycin resistance in patients with helicobacter pylori infection (2001) (0)
Genotype and Phenotype Patterns of Human Immunodeﬁciency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment (2004) (0)
[Effects of thymectomy on the natural bactericidal power of thymectomized mice]. (1975) (0)
389 Comparison of hepatitis C virus population in plasma, peripheral blood mononuclear cells (PBMC) and cerebrospinal fluid (CSF) of HIV/HCV coinfected patients (2004) (0)
SAT-220-Higher frequency of occult HCV infection in HIV/HCV coinfected patients with advanced liver disease: Post DAAs treatment observation (2019) (0)
CD4 T lymphocyte dynamics and evolution in naive HIV+ patients treated with antiviral therapy: mathematical modelling for therapy decision making (2012) (0)
Improvement of CXCR 3 ligand CXCL 11 / I-TAC measurement in human plasma and serum (2009) (0)
[Generalized and persistent lymphadenopathy in drug addicts: clinical and epidemiological aspects]. (1984) (0)
Trastuzumab resistance: Bringing tailored therapy to the clinic (2008) (0)
Prophylactic and therapeutic guidelines for yeast mucosal infections in HIV-infected individuals (1997) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Phase I preventative clinical trial with the Tat vaccine (ISS P-001) and long term follow-up (2011) (0)
Neuroradiological Evaluation of AIDS Patients: A Prospective Study (1989) (0)
Letter: Phagocyte function in systemic lupus erythematosus. (1975) (0)
Interleukin-2 for the Treatment of HIV Infection (2003) (0)
Immunologic reconstitution by interleukin-2: facts and open questions. (2000) (0)
Long-term Effectiveness of Recommanded Boosted PI-Based Antiretroviral Therapy in Europe (2014) (0)
Clindamycin plus primaquine therapy for Pneumocystis carinii pneumonia in AIDS patients. (1990) (0)
Deficient natural-cell mediated immunity against "Salmonella typhi" in patients with LAS and AIDS. (1986) (0)
PHARMACOKINETIC STUDY OF THE LIPOSOMALEN CAPSULATED DAUNORUBICIN (DAUNOXOME) IN PATIENTS WITH HIV-ASSOCIATED KAPOSI'S SARCOMA (1999) (0)
Efficacy and Safety of Rilpivirine-Based Antiretroviral Therapy in Treatment-Naïve and Treatment-Experienced HIV-1-Positive Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (2021) (0)
Central nervous system immune reconstitution disease presenting with vasculitis-like lesions (2009) (0)
Dolutegravir: a new option for HIV treatment (2014) (0)
60PV Related Lesions in HIV Positive Subjects on HAART: Study of Viral Markers of Cervical Neoplasia Progression (2005) (0)
Primary HIV infection: clinical aspects and monitoring. (1997) (0)
Comparison of a commercial and an in-house T cell-based assay for the diagnosis of Mycobacterium tuberculosis infection. (2007) (0)
ValueofCytomegalovirus Culture FromBALFluid andCorrelation WithLung Disease (2017) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Rapid detection of helicobacter Pylori (Hp) resistance to clarithromycin by double gradient-denaturing gel electrophoresis (DG-DGGE) from gastric biopsies of HIV infected patients (2000) (0)
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial. (2018) (0)
Influence of gender in predicting CCR5 coreceptor usage (2008) (0)
P1240 CHARACTERIZATION OF HCV-1 SUBTYPES AND NATURAL RESISTANCE TO PROTEASE INHIBITORS IN LIVER AND PLASMA COMPARTMENTS OF HIV/HCV COINFECTED INDIVIDUALS (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
A case of HIV-associated fever of unknown origin: deficit of IL-1beta antagonistic activity and resolution with monocyte-granulocyte apheresis. (2006) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
HIV-IgM serology (1988) (0)
Selected Abstracts (2000) (0)
Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a. (2004) (0)
Clinical considerations on 11 cases of cryptococcal infection in subjects affected with AIDS (1988) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply. (2015) (0)
Mononuclear Cells and in the U937 Cell Line Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood (2013) (0)
NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B (2017) (0)
Prevalence of a 660 amino acid substitution in the PePHD region of HCV-E2 protein in hepatocellular carcinoma (2002) (0)
PNPLA3 variant is an independent predictor of severe steatosis in patients with cronic hepatitis C and HIV infection (2015) (0)
The thymic hormones in the treatment of immune deficiency related to HIV infection. (1992) (0)
and in the U 937 Cell Line Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood (1997) (0)
Monitoring of progressive multifocal leukoencephalopathy by measuring plasma JCV DNA level (2013) (0)
Giardia intestinalis infection in patients affected with AIDS (1988) (0)
High maraviroc plasma concentration and severe polyneuropathy in a HIV-positive kidney transplant recipient (2012) (0)
New evidences supporting HIV-1 transmission during a bloody fight between two adults (1998) (0)
EEG and auditory P300 mapping in HIV + subjects: Preliminar results (1993) (0)
condition associated with reduced survival . patients with AIDS : a relatively uncommon Acute upper gastrointestinal bleeding in (2006) (0)
Doses and side effects of co-trimoxazole in treatment of AIDS associated pneumocystis carinii pneumonia. (1987) (0)
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen. (2023) (0)
Chronically Infected Promonocytic U1 Cells Macrophages and Virus Expression in Inhibits HIV Replication in Human The Binding Subunit of Pertussis Toxin (2001) (0)
Value of Immunostimolant Drugs in the Treatment of Burns (1981) (0)
Il processo infiammatorio. (1990) (0)
Reply (1992) (0)
Virus Infection Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency (1999) (0)
Budget Impact Analysis of The Use of Daclatasvir for The Treatment of Hepatitis C Virus (Hcv) Genotypes 3, In The Italian Setting. (2015) (0)
Humoral immune response following HIV infection (1989) (0)
P.414 Clinical course of chronic hepatitis in HCV/HIV coinfected patients: the lesson from sequential liver biopsies (2006) (0)
1195 TEMPORAL DYNAMIC OF MUTATIONS ASSOCIATED WITH HCV PROTEASE INHIBITORS RESISTANCE IN NATURAL STRAINS OF HIV/HCV COINFECTED INDIVIDUALS (2012) (0)
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens (2011) (0)
Baseline mRNA levels are the only independent virological marker of viral suppression (2000) (0)
Severe staphylococcus aureus infections in patients pts with aids (1990) (0)
The NS3 protease gene of HCV is highly conserved within the putative catalytic site region (2003) (0)
High plasma levels of parathyroid hormone (PTH) are associated with an increased cardiovascular risk among HIV-infected subjects (2010) (0)
Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients. (1987) (0)
HIV-1 In Vitro Neutralize the Infectivity of R 5 Strains of Down-Modulate Surface CCR 5 In Vivo and Partners of HIV-Seropositive Individuals CCR 5-Reactive Antibodies in Seronegative (2000) (0)
[A proposal for the diagnosis, staging and therapy of epidemic Kaposi's sarcoma]. (1988) (0)
Comparison of the Phoenix automated system , the Etest method and broth microdilution in determining temocillin susceptibility of Enterobacteriaceae (2013) (0)
Effect of alpha-fetoprotein on survival in HIV-infected patients with hepatocellular carcinoma (2019) (0)
Disseminated aspergillosis. (1982) (0)
Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients (2016) (0)
TITLE : 3 Dynamics of adaptive and innate immunity in patients treated during Primary 4 HIV Infection : results from MAIN randomised clinical trial (2015) (0)
Current classification for epidemic Kaposi's sarcoma (EKS) (1994) (0)
using phenol-chloroform or silica particles. Detection of hepatitis C virus RNA by methods (2013) (0)
P19 Response to second‐line protease‐inhibitor (PI) regimens: results from the EuroSIDA study (2000) (0)
[Transitory increase of OKT4+ lymphocytes in the peripheral blood of patients with lymphadenopathy syndrome treated with beta-interferon]. (1985) (0)
Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine. (2013) (0)
A prospective, randomised, placebo-controlled study of the treatment of primary HIV infection with zidovudine (1992) (0)
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing. (2022) (0)
Adherence of hiv patients switching to emtricitabina+tenofovir disoproxil+rilpivirin. Real world evidence from italian administrative databases. (2015) (0)
P12.06 Consumption Decrease of Carbapenems in a Teaching Hospital After Guidelines Introduction and Formulary Restrictions; Results from the First Year of Survey (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Adriano Lazzarin?

Adriano Lazzarin is affiliated with the following schools:

Adriano Lazzarin's Academic­Influence.com Rankings

Adriano Lazzarin's Degrees

Similar Degrees You Can Earn

Why Is Adriano Lazzarin Influential?

Adriano Lazzarin's Published Works

Published Works

What Schools Are Affiliated With Adriano Lazzarin?

Adriano Lazzarin's AcademicInfluence.com Rankings